Alterity Therapeutics stock more than doubled on Tuesday after the company announced new data for its lead drug candidate for the treatment of multiple system atrophy.
Alterity Therapeutics says it has received an update from the FDA regarding its Parkinson’s treatment. That made shareholders happy.